Cynthia Epperson
Concepts (516)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Premenstrual Syndrome | 17 | 2023 | 27 | 5.190 |
Why?
| Pregnancy Complications | 21 | 2018 | 430 | 4.420 |
Why?
| Depression, Postpartum | 17 | 2022 | 101 | 3.880 |
Why?
| Premenstrual Dysphoric Disorder | 12 | 2023 | 16 | 3.390 |
Why?
| Menopause | 13 | 2023 | 271 | 3.330 |
Why?
| Stress, Psychological | 13 | 2023 | 944 | 3.260 |
Why?
| Sex Characteristics | 13 | 2021 | 636 | 3.130 |
Why?
| Depressive Disorder, Major | 14 | 2023 | 301 | 2.990 |
Why?
| Depression | 20 | 2023 | 1133 | 2.400 |
Why?
| Brain | 18 | 2022 | 2355 | 2.060 |
Why?
| Mood Disorders | 7 | 2020 | 112 | 2.030 |
Why?
| Gonadal Steroid Hormones | 6 | 2018 | 123 | 2.020 |
Why?
| Mental Disorders | 10 | 2018 | 889 | 2.010 |
Why?
| gamma-Aminobutyric Acid | 11 | 2023 | 144 | 2.000 |
Why?
| Executive Function | 8 | 2023 | 380 | 1.900 |
Why?
| Female | 133 | 2023 | 59324 | 1.820 |
Why?
| Depressive Disorder | 8 | 2017 | 330 | 1.670 |
Why?
| Prefrontal Cortex | 6 | 2018 | 263 | 1.670 |
Why?
| Reflex, Startle | 3 | 2022 | 57 | 1.670 |
Why?
| Perimenopause | 4 | 2023 | 61 | 1.580 |
Why?
| Prenatal Exposure Delayed Effects | 5 | 2019 | 453 | 1.570 |
Why?
| Antidepressive Agents | 11 | 2018 | 195 | 1.500 |
Why?
| Sleep Initiation and Maintenance Disorders | 2 | 2023 | 119 | 1.450 |
Why?
| Cognition | 8 | 2023 | 990 | 1.430 |
Why?
| Substance Withdrawal Syndrome | 2 | 2022 | 159 | 1.400 |
Why?
| Menstrual Cycle | 9 | 2022 | 108 | 1.380 |
Why?
| Pregnancy | 36 | 2023 | 5499 | 1.370 |
Why?
| Biomedical Research | 3 | 2021 | 582 | 1.350 |
Why?
| Humans | 144 | 2023 | 114045 | 1.340 |
Why?
| Memory, Short-Term | 6 | 2020 | 227 | 1.340 |
Why?
| Anxiety | 12 | 2022 | 843 | 1.320 |
Why?
| Sex Factors | 13 | 2021 | 1706 | 1.290 |
Why?
| Tryptophan | 7 | 2020 | 136 | 1.280 |
Why?
| Stress, Physiological | 4 | 2019 | 379 | 1.250 |
Why?
| Psychotherapy | 8 | 2018 | 149 | 1.110 |
Why?
| Serotonin | 7 | 2020 | 292 | 1.110 |
Why?
| Lower Urinary Tract Symptoms | 4 | 2020 | 47 | 1.110 |
Why?
| Longevity | 2 | 2019 | 136 | 1.060 |
Why?
| Lisdexamfetamine Dimesylate | 2 | 2016 | 4 | 1.040 |
Why?
| Progesterone | 9 | 2023 | 232 | 1.030 |
Why?
| Transgender Persons | 2 | 2018 | 134 | 1.020 |
Why?
| Hypothalamo-Hypophyseal System | 6 | 2023 | 164 | 1.020 |
Why?
| Stress Disorders, Post-Traumatic | 5 | 2019 | 757 | 1.010 |
Why?
| Postmenopause | 4 | 2023 | 301 | 1.000 |
Why?
| Smoking Cessation | 4 | 2022 | 374 | 0.990 |
Why?
| Adult | 68 | 2022 | 30375 | 0.980 |
Why?
| Child Abuse | 3 | 2020 | 456 | 0.970 |
Why?
| Estradiol | 11 | 2023 | 450 | 0.970 |
Why?
| Transcranial Magnetic Stimulation | 2 | 2018 | 44 | 0.950 |
Why?
| Cross-Over Studies | 9 | 2022 | 439 | 0.940 |
Why?
| Pregnant Women | 2 | 2018 | 129 | 0.940 |
Why?
| Central Nervous System Stimulants | 2 | 2016 | 140 | 0.920 |
Why?
| C-Reactive Protein | 2 | 2023 | 362 | 0.880 |
Why?
| Psychiatric Status Rating Scales | 12 | 2022 | 481 | 0.870 |
Why?
| Gender Identity | 3 | 2018 | 100 | 0.850 |
Why?
| Magnetic Resonance Imaging | 9 | 2023 | 3039 | 0.840 |
Why?
| Urinalysis | 1 | 2023 | 64 | 0.840 |
Why?
| Positron-Emission Tomography | 3 | 2020 | 260 | 0.840 |
Why?
| Obsessive-Compulsive Disorder | 8 | 2010 | 32 | 0.820 |
Why?
| Ethics Committees, Research | 2 | 2020 | 38 | 0.820 |
Why?
| Pituitary-Adrenal System | 4 | 2019 | 130 | 0.810 |
Why?
| Hydrocortisone | 3 | 2019 | 267 | 0.810 |
Why?
| Pregnanolone | 6 | 2023 | 20 | 0.800 |
Why?
| Double-Blind Method | 14 | 2022 | 1656 | 0.790 |
Why?
| Prenatal Diagnosis | 1 | 2023 | 163 | 0.770 |
Why?
| Psychopharmacology | 1 | 2021 | 7 | 0.770 |
Why?
| Transsexualism | 2 | 2018 | 17 | 0.760 |
Why?
| Affect | 6 | 2023 | 246 | 0.740 |
Why?
| Emotions | 5 | 2023 | 474 | 0.740 |
Why?
| Estrogens | 4 | 2020 | 312 | 0.730 |
Why?
| Cognition Disorders | 3 | 2017 | 476 | 0.710 |
Why?
| Glutamic Acid | 5 | 2018 | 210 | 0.700 |
Why?
| Sertraline | 4 | 2023 | 26 | 0.690 |
Why?
| Tobacco Use Disorder | 1 | 2022 | 234 | 0.690 |
Why?
| Therapy, Computer-Assisted | 3 | 2017 | 58 | 0.690 |
Why?
| Smoking | 5 | 2022 | 1382 | 0.690 |
Why?
| Attention | 2 | 2015 | 394 | 0.690 |
Why?
| Life Change Events | 3 | 2017 | 135 | 0.680 |
Why?
| Sleep Wake Disorders | 1 | 2023 | 232 | 0.670 |
Why?
| Middle Aged | 39 | 2020 | 26605 | 0.670 |
Why?
| Health Resources | 1 | 2020 | 120 | 0.640 |
Why?
| Nicotine | 3 | 2022 | 265 | 0.640 |
Why?
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2015 | 230 | 0.630 |
Why?
| Interdisciplinary Research | 1 | 2019 | 25 | 0.620 |
Why?
| Cost of Illness | 1 | 2020 | 254 | 0.610 |
Why?
| Acoustic Stimulation | 2 | 2018 | 306 | 0.600 |
Why?
| Mental Health | 3 | 2022 | 559 | 0.580 |
Why?
| Resilience, Psychological | 1 | 2019 | 95 | 0.580 |
Why?
| Patient Dropouts | 1 | 2018 | 66 | 0.580 |
Why?
| Premature Birth | 4 | 2017 | 275 | 0.570 |
Why?
| Immune System | 1 | 2018 | 171 | 0.560 |
Why?
| Puerperal Disorders | 2 | 2010 | 30 | 0.560 |
Why?
| Urinary Bladder, Overactive | 2 | 2019 | 20 | 0.550 |
Why?
| Dementia | 2 | 2016 | 186 | 0.530 |
Why?
| Male | 41 | 2023 | 55396 | 0.530 |
Why?
| Young Adult | 20 | 2022 | 10444 | 0.530 |
Why?
| Magnetic Resonance Spectroscopy | 6 | 2012 | 474 | 0.520 |
Why?
| Cigarette Smoking | 1 | 2017 | 74 | 0.510 |
Why?
| Ovarian Neoplasms | 1 | 2020 | 386 | 0.500 |
Why?
| Treatment Outcome | 21 | 2022 | 9049 | 0.500 |
Why?
| Occipital Lobe | 5 | 2006 | 23 | 0.500 |
Why?
| Brain-Derived Neurotrophic Factor | 2 | 2014 | 106 | 0.490 |
Why?
| Surveys and Questionnaires | 12 | 2022 | 4595 | 0.490 |
Why?
| Postpartum Period | 6 | 2022 | 275 | 0.490 |
Why?
| Inflammation | 3 | 2023 | 2464 | 0.480 |
Why?
| Outpatients | 1 | 2018 | 325 | 0.470 |
Why?
| Bipolar Disorder | 3 | 2011 | 203 | 0.470 |
Why?
| Cytokines | 2 | 2019 | 1824 | 0.470 |
Why?
| Patient Acceptance of Health Care | 3 | 2017 | 675 | 0.470 |
Why?
| Monoamine Oxidase | 1 | 2014 | 27 | 0.470 |
Why?
| Quality of Life | 4 | 2019 | 2343 | 0.460 |
Why?
| Luteal Phase | 5 | 2022 | 41 | 0.450 |
Why?
| Patient Compliance | 1 | 2018 | 524 | 0.450 |
Why?
| Platelet Aggregation | 1 | 2014 | 90 | 0.440 |
Why?
| Memory | 2 | 2013 | 209 | 0.440 |
Why?
| Antipsychotic Agents | 4 | 2006 | 183 | 0.440 |
Why?
| Research Design | 2 | 2017 | 919 | 0.430 |
Why?
| Imaging, Three-Dimensional | 2 | 2016 | 511 | 0.430 |
Why?
| Abnormalities, Drug-Induced | 1 | 2013 | 10 | 0.430 |
Why?
| Image Processing, Computer-Assisted | 2 | 2018 | 684 | 0.430 |
Why?
| Estrus | 1 | 2012 | 11 | 0.410 |
Why?
| Neurotransmitter Agents | 2 | 2018 | 75 | 0.410 |
Why?
| Libido | 2 | 2023 | 24 | 0.410 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2012 | 22 | 0.400 |
Why?
| Sexual Maturation | 1 | 2012 | 47 | 0.400 |
Why?
| Seasonal Affective Disorder | 2 | 2011 | 9 | 0.400 |
Why?
| Amines | 1 | 2012 | 34 | 0.400 |
Why?
| Gastrointestinal Microbiome | 1 | 2018 | 502 | 0.400 |
Why?
| Adolescent | 16 | 2023 | 17800 | 0.400 |
Why?
| Steroids | 2 | 2018 | 143 | 0.390 |
Why?
| Neuropsychological Tests | 7 | 2020 | 926 | 0.390 |
Why?
| Neuroimaging | 4 | 2022 | 249 | 0.390 |
Why?
| Smokers | 2 | 2022 | 129 | 0.390 |
Why?
| Propylamines | 1 | 2011 | 11 | 0.380 |
Why?
| Adrenergic Uptake Inhibitors | 1 | 2011 | 13 | 0.370 |
Why?
| Blood Platelets | 2 | 2004 | 326 | 0.370 |
Why?
| Fluoxetine | 5 | 2006 | 46 | 0.370 |
Why?
| Pregnancy Outcome | 1 | 2013 | 337 | 0.360 |
Why?
| Reproductive History | 1 | 2010 | 12 | 0.350 |
Why?
| Aging | 3 | 2015 | 1611 | 0.340 |
Why?
| Memory Disorders | 1 | 2011 | 153 | 0.340 |
Why?
| Animals | 14 | 2020 | 31565 | 0.340 |
Why?
| Trichotillomania | 3 | 1999 | 6 | 0.340 |
Why?
| Pregnanes | 2 | 2006 | 3 | 0.330 |
Why?
| Naltrexone | 1 | 2010 | 82 | 0.330 |
Why?
| Behavior, Animal | 1 | 2012 | 459 | 0.320 |
Why?
| Narcotic Antagonists | 1 | 2010 | 135 | 0.310 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2014 | 1880 | 0.310 |
Why?
| Oxygen | 1 | 2013 | 851 | 0.310 |
Why?
| National Institutes of Health (U.S.) | 2 | 2020 | 105 | 0.300 |
Why?
| Women's Health | 3 | 2017 | 270 | 0.300 |
Why?
| Hormone Replacement Therapy | 2 | 2018 | 76 | 0.300 |
Why?
| Prevalence | 7 | 2022 | 2247 | 0.300 |
Why?
| Anxiety Disorders | 3 | 2021 | 304 | 0.300 |
Why?
| Endothelium, Vascular | 1 | 2014 | 830 | 0.300 |
Why?
| beta-Cyclodextrins | 2 | 2018 | 28 | 0.290 |
Why?
| Reproducibility of Results | 5 | 2021 | 2764 | 0.290 |
Why?
| Interleukin-6 | 2 | 2023 | 673 | 0.290 |
Why?
| Phototherapy | 2 | 2004 | 24 | 0.280 |
Why?
| Risk Factors | 8 | 2019 | 8614 | 0.270 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2023 | 1128 | 0.260 |
Why?
| Oxytocin | 2 | 1996 | 45 | 0.260 |
Why?
| Self Report | 3 | 2020 | 695 | 0.260 |
Why?
| Pilot Projects | 5 | 2018 | 1360 | 0.250 |
Why?
| Prolactin | 1 | 2006 | 96 | 0.250 |
Why?
| Cross-Sectional Studies | 6 | 2023 | 4402 | 0.250 |
Why?
| Fatty Acids, Omega-3 | 2 | 2018 | 122 | 0.250 |
Why?
| Gestational Age | 2 | 2023 | 761 | 0.240 |
Why?
| HIV Infections | 1 | 2019 | 2453 | 0.240 |
Why?
| Maternal Behavior | 2 | 2016 | 69 | 0.240 |
Why?
| Aged | 11 | 2020 | 18969 | 0.240 |
Why?
| Puberty | 1 | 2006 | 135 | 0.230 |
Why?
| Risperidone | 3 | 2000 | 26 | 0.230 |
Why?
| Hospitalization | 1 | 2013 | 1762 | 0.230 |
Why?
| Epilepsy | 1 | 2008 | 278 | 0.230 |
Why?
| Medicaid | 2 | 2018 | 404 | 0.220 |
Why?
| Socioeconomic Factors | 4 | 2017 | 1080 | 0.220 |
Why?
| Nocturia | 2 | 2020 | 7 | 0.220 |
Why?
| Prenatal Care | 2 | 2017 | 250 | 0.210 |
Why?
| United States | 8 | 2023 | 12137 | 0.210 |
Why?
| Child | 8 | 2020 | 18401 | 0.210 |
Why?
| Maternal Exposure | 1 | 2004 | 138 | 0.210 |
Why?
| Health Status | 2 | 2020 | 716 | 0.210 |
Why?
| Pirenzepine | 2 | 1999 | 7 | 0.210 |
Why?
| Comorbidity | 6 | 2018 | 1447 | 0.200 |
Why?
| Premenopause | 1 | 2023 | 105 | 0.200 |
Why?
| Acoustics | 1 | 2022 | 46 | 0.200 |
Why?
| Consensus | 2 | 2016 | 532 | 0.200 |
Why?
| Serotonin Antagonists | 3 | 2000 | 30 | 0.200 |
Why?
| Medically Unexplained Symptoms | 1 | 2022 | 4 | 0.200 |
Why?
| Milk, Human | 1 | 2003 | 127 | 0.200 |
Why?
| Sexual Behavior | 2 | 2023 | 434 | 0.200 |
Why?
| Longitudinal Studies | 3 | 2020 | 2384 | 0.190 |
Why?
| Urination | 1 | 2022 | 40 | 0.190 |
Why?
| Administration, Cutaneous | 3 | 2011 | 117 | 0.190 |
Why?
| Health Priorities | 1 | 2021 | 34 | 0.190 |
Why?
| Urinary Bladder | 2 | 2020 | 161 | 0.190 |
Why?
| Cohort Studies | 5 | 2020 | 4883 | 0.190 |
Why?
| Contraceptive Agents | 1 | 2022 | 54 | 0.190 |
Why?
| Pennsylvania | 2 | 2018 | 94 | 0.180 |
Why?
| Epigenesis, Genetic | 3 | 2020 | 518 | 0.180 |
Why?
| Norpregnadienes | 1 | 2020 | 7 | 0.180 |
Why?
| Fatigue | 1 | 2022 | 294 | 0.180 |
Why?
| Reward | 1 | 2023 | 211 | 0.180 |
Why?
| RNA, Small Untranslated | 1 | 2020 | 15 | 0.180 |
Why?
| White Matter | 1 | 2022 | 105 | 0.180 |
Why?
| Salpingo-oophorectomy | 1 | 2020 | 11 | 0.180 |
Why?
| Contraception | 1 | 2022 | 117 | 0.180 |
Why?
| Sexual and Gender Minorities | 1 | 2023 | 138 | 0.170 |
Why?
| Animal Care Committees | 1 | 2020 | 6 | 0.170 |
Why?
| Cues | 1 | 2022 | 301 | 0.170 |
Why?
| Nerve Net | 2 | 2020 | 227 | 0.170 |
Why?
| BRCA2 Protein | 1 | 2020 | 41 | 0.170 |
Why?
| Follow-Up Studies | 5 | 2018 | 4392 | 0.170 |
Why?
| BRCA1 Protein | 1 | 2020 | 56 | 0.170 |
Why?
| Spermatozoa | 1 | 2020 | 84 | 0.170 |
Why?
| Breast Feeding | 3 | 2014 | 366 | 0.170 |
Why?
| Ovariectomy | 1 | 2020 | 116 | 0.170 |
Why?
| Hypogonadism | 1 | 2020 | 75 | 0.170 |
Why?
| Administration, Oral | 2 | 2012 | 725 | 0.170 |
Why?
| Menstruation | 2 | 2012 | 35 | 0.170 |
Why?
| Sex Distribution | 1 | 2020 | 336 | 0.160 |
Why?
| Cerebral Cortex | 1 | 2002 | 380 | 0.160 |
Why?
| United States Food and Drug Administration | 1 | 2020 | 172 | 0.160 |
Why?
| Propensity Score | 1 | 2020 | 225 | 0.160 |
Why?
| Telemedicine | 2 | 2017 | 662 | 0.160 |
Why?
| History, 20th Century | 1 | 2020 | 265 | 0.160 |
Why?
| Protons | 2 | 2012 | 73 | 0.160 |
Why?
| Benzodiazepines | 3 | 2014 | 114 | 0.160 |
Why?
| Fetus | 1 | 2023 | 698 | 0.160 |
Why?
| Receptors, GABA | 1 | 2018 | 8 | 0.160 |
Why?
| GABA Agonists | 1 | 2018 | 14 | 0.160 |
Why?
| Occupations | 1 | 2018 | 35 | 0.150 |
Why?
| Gender Dysphoria | 1 | 2018 | 13 | 0.150 |
Why?
| Cause of Death | 1 | 2020 | 362 | 0.150 |
Why?
| Neurobiology | 1 | 2018 | 16 | 0.150 |
Why?
| Psychophysiology | 1 | 2018 | 16 | 0.150 |
Why?
| N-Acetylglucosaminyltransferases | 1 | 2018 | 22 | 0.150 |
Why?
| Fatty Acids, Unsaturated | 1 | 2018 | 84 | 0.150 |
Why?
| Mothers | 2 | 2014 | 650 | 0.150 |
Why?
| Obstetric Labor Complications | 1 | 2017 | 30 | 0.150 |
Why?
| Melatonin | 2 | 2011 | 106 | 0.140 |
Why?
| Glutamine | 2 | 2016 | 91 | 0.140 |
Why?
| Population Surveillance | 1 | 2020 | 385 | 0.140 |
Why?
| Gene-Environment Interaction | 1 | 2018 | 182 | 0.140 |
Why?
| Health Care Costs | 1 | 2020 | 381 | 0.140 |
Why?
| Precision Medicine | 1 | 2020 | 335 | 0.140 |
Why?
| Self Concept | 1 | 2018 | 211 | 0.140 |
Why?
| Monitoring, Ambulatory | 1 | 2017 | 81 | 0.140 |
Why?
| Child of Impaired Parents | 1 | 2017 | 40 | 0.140 |
Why?
| Ecosystem | 1 | 2021 | 500 | 0.140 |
Why?
| Perinatal Care | 1 | 2017 | 36 | 0.140 |
Why?
| Family Conflict | 1 | 2017 | 36 | 0.140 |
Why?
| Domestic Violence | 1 | 2017 | 41 | 0.140 |
Why?
| Infant, Newborn | 6 | 2014 | 5038 | 0.130 |
Why?
| Commission on Professional and Hospital Activities | 1 | 2016 | 3 | 0.130 |
Why?
| Adult Survivors of Child Adverse Events | 1 | 2016 | 10 | 0.130 |
Why?
| Retrospective Studies | 4 | 2022 | 12521 | 0.130 |
Why?
| Radionuclide Imaging | 1 | 2016 | 115 | 0.130 |
Why?
| Child Abuse, Sexual | 1 | 2017 | 81 | 0.130 |
Why?
| Cross-Cultural Comparison | 1 | 2016 | 77 | 0.130 |
Why?
| RNA, Ribosomal, 16S | 1 | 2018 | 485 | 0.130 |
Why?
| Interleukin-1beta | 1 | 2018 | 368 | 0.130 |
Why?
| Adrenal Glands | 1 | 2016 | 66 | 0.130 |
Why?
| Feces | 1 | 2018 | 372 | 0.130 |
Why?
| Polycystic Ovary Syndrome | 1 | 2018 | 141 | 0.130 |
Why?
| Patient Care Management | 1 | 2016 | 53 | 0.130 |
Why?
| Standard of Care | 1 | 2016 | 62 | 0.130 |
Why?
| Fear | 1 | 2018 | 292 | 0.120 |
Why?
| Feasibility Studies | 2 | 2017 | 735 | 0.120 |
Why?
| Mobile Applications | 1 | 2017 | 140 | 0.120 |
Why?
| Obesity | 2 | 2018 | 2505 | 0.120 |
Why?
| Transcriptome | 1 | 2020 | 723 | 0.120 |
Why?
| Patient Preference | 1 | 2017 | 164 | 0.120 |
Why?
| Testosterone | 1 | 2018 | 341 | 0.120 |
Why?
| Ultrasonography, Prenatal | 1 | 2016 | 237 | 0.120 |
Why?
| Fetal Development | 2 | 2018 | 248 | 0.120 |
Why?
| Astronauts | 1 | 2014 | 18 | 0.120 |
Why?
| Placebos | 2 | 2013 | 197 | 0.120 |
Why?
| Behavioral Research | 1 | 2014 | 34 | 0.120 |
Why?
| Urban Population | 1 | 2017 | 396 | 0.120 |
Why?
| Poverty | 1 | 2018 | 440 | 0.120 |
Why?
| Mental Recall | 1 | 2015 | 171 | 0.110 |
Why?
| Drug Therapy, Combination | 5 | 2006 | 949 | 0.110 |
Why?
| Ultrasonography, Doppler | 1 | 2014 | 104 | 0.110 |
Why?
| Patient Satisfaction | 2 | 2014 | 571 | 0.110 |
Why?
| Gyrus Cinguli | 1 | 2014 | 70 | 0.110 |
Why?
| Circadian Rhythm | 3 | 2014 | 356 | 0.110 |
Why?
| Weight Loss | 1 | 2018 | 642 | 0.110 |
Why?
| Histones | 1 | 2018 | 529 | 0.110 |
Why?
| Space Flight | 1 | 2014 | 127 | 0.110 |
Why?
| Mental Health Services | 1 | 2017 | 316 | 0.110 |
Why?
| Acute Disease | 2 | 2020 | 907 | 0.110 |
Why?
| Psychotherapy, Brief | 1 | 2013 | 27 | 0.110 |
Why?
| Rodentia | 1 | 2013 | 43 | 0.110 |
Why?
| Brachial Artery | 1 | 2014 | 176 | 0.100 |
Why?
| Frontal Lobe | 1 | 2014 | 141 | 0.100 |
Why?
| Behavior | 2 | 2020 | 91 | 0.100 |
Why?
| Brain Chemistry | 2 | 2007 | 114 | 0.100 |
Why?
| Severity of Illness Index | 4 | 2018 | 2537 | 0.100 |
Why?
| Infant, Low Birth Weight | 1 | 2013 | 124 | 0.100 |
Why?
| Blood Flow Velocity | 1 | 2014 | 388 | 0.100 |
Why?
| Placenta | 1 | 2018 | 628 | 0.100 |
Why?
| Heart Rate | 1 | 2016 | 710 | 0.100 |
Why?
| Delirium | 1 | 2013 | 66 | 0.100 |
Why?
| Cost-Benefit Analysis | 1 | 2014 | 544 | 0.100 |
Why?
| Disease Management | 1 | 2015 | 556 | 0.100 |
Why?
| Alzheimer Disease | 1 | 2016 | 442 | 0.090 |
Why?
| Adaptation, Psychological | 1 | 2016 | 545 | 0.090 |
Why?
| Diagnosis, Differential | 1 | 2015 | 1331 | 0.090 |
Why?
| Atomoxetine Hydrochloride | 1 | 2011 | 4 | 0.090 |
Why?
| Diet | 1 | 2018 | 1080 | 0.090 |
Why?
| Patient Education as Topic | 2 | 2010 | 666 | 0.090 |
Why?
| Patients | 1 | 2013 | 163 | 0.090 |
Why?
| Peripartum Period | 1 | 2011 | 9 | 0.090 |
Why?
| Body Weight | 2 | 2018 | 868 | 0.090 |
Why?
| Vasodilation | 1 | 2014 | 418 | 0.090 |
Why?
| Prescription Drugs | 1 | 2013 | 116 | 0.090 |
Why?
| Functional Neuroimaging | 1 | 2011 | 71 | 0.090 |
Why?
| Case-Control Studies | 2 | 2016 | 3003 | 0.090 |
Why?
| Projection | 1 | 2010 | 3 | 0.090 |
Why?
| Pregnancy, High-Risk | 1 | 2010 | 12 | 0.090 |
Why?
| Psychoanalytic Therapy | 1 | 2010 | 10 | 0.090 |
Why?
| Electron Transport Chain Complex Proteins | 1 | 2010 | 18 | 0.090 |
Why?
| Psychomotor Performance | 2 | 2011 | 281 | 0.090 |
Why?
| Disease Models, Animal | 2 | 2018 | 3498 | 0.090 |
Why?
| Object Attachment | 1 | 2010 | 33 | 0.090 |
Why?
| Anticonvulsants | 1 | 2012 | 178 | 0.090 |
Why?
| Apoptotic Protease-Activating Factor 1 | 1 | 2010 | 2 | 0.090 |
Why?
| Menarche | 1 | 2010 | 49 | 0.090 |
Why?
| Mutation | 1 | 2020 | 3338 | 0.080 |
Why?
| Parturition | 1 | 2010 | 54 | 0.080 |
Why?
| Boston | 2 | 2020 | 76 | 0.080 |
Why?
| Brain Mapping | 3 | 2020 | 521 | 0.080 |
Why?
| Professional-Patient Relations | 1 | 2010 | 140 | 0.080 |
Why?
| Seasons | 1 | 2011 | 440 | 0.080 |
Why?
| Nitric Oxide | 1 | 2014 | 817 | 0.080 |
Why?
| Fluvoxamine | 3 | 1999 | 12 | 0.080 |
Why?
| Follicular Phase | 2 | 2014 | 36 | 0.080 |
Why?
| Antimanic Agents | 1 | 2009 | 14 | 0.080 |
Why?
| Estrogen Replacement Therapy | 2 | 2015 | 116 | 0.080 |
Why?
| Critical Care | 1 | 2013 | 472 | 0.080 |
Why?
| Time Factors | 3 | 2018 | 6077 | 0.080 |
Why?
| Triazines | 1 | 2009 | 36 | 0.080 |
Why?
| Age of Onset | 1 | 2010 | 444 | 0.080 |
Why?
| Alleles | 2 | 2010 | 789 | 0.080 |
Why?
| Aged, 80 and over | 3 | 2020 | 6306 | 0.080 |
Why?
| Recurrence | 2 | 2013 | 925 | 0.080 |
Why?
| Logistic Models | 1 | 2013 | 1829 | 0.080 |
Why?
| Health Services Accessibility | 1 | 2014 | 756 | 0.080 |
Why?
| Fetal Growth Retardation | 1 | 2013 | 470 | 0.080 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 959 | 0.080 |
Why?
| Interviews as Topic | 1 | 2010 | 575 | 0.070 |
Why?
| Amino Acids | 1 | 2011 | 445 | 0.070 |
Why?
| Odds Ratio | 1 | 2010 | 951 | 0.070 |
Why?
| Data Collection | 1 | 2010 | 618 | 0.070 |
Why?
| Aspartic Acid | 2 | 2005 | 77 | 0.070 |
Why?
| Azetidines | 1 | 2007 | 31 | 0.070 |
Why?
| Drug Combinations | 2 | 2018 | 286 | 0.070 |
Why?
| Administration, Intranasal | 2 | 1996 | 75 | 0.070 |
Why?
| Arousal | 1 | 2007 | 152 | 0.070 |
Why?
| Gonadal Disorders | 1 | 2006 | 1 | 0.070 |
Why?
| Photic Stimulation | 1 | 2007 | 203 | 0.060 |
Why?
| Verbal Learning | 1 | 2006 | 63 | 0.060 |
Why?
| Dehydroepiandrosterone | 1 | 2006 | 49 | 0.060 |
Why?
| Medication Adherence | 1 | 2010 | 531 | 0.060 |
Why?
| Hormones | 1 | 2006 | 132 | 0.060 |
Why?
| Receptors, Nicotinic | 1 | 2007 | 273 | 0.060 |
Why?
| Suicidal Ideation | 2 | 2022 | 402 | 0.060 |
Why?
| Visual Perception | 1 | 2006 | 140 | 0.060 |
Why?
| Health Surveys | 2 | 2019 | 441 | 0.060 |
Why?
| Gene Expression Profiling | 3 | 2018 | 1518 | 0.060 |
Why?
| Cotinine | 1 | 2005 | 69 | 0.060 |
Why?
| Pyridines | 1 | 2007 | 419 | 0.060 |
Why?
| Androsterone | 1 | 2023 | 2 | 0.060 |
Why?
| Lung Neoplasms | 1 | 2016 | 2159 | 0.060 |
Why?
| Chronic Disease | 2 | 2020 | 1577 | 0.060 |
Why?
| Ketanserin | 1 | 2003 | 12 | 0.050 |
Why?
| Half-Life | 1 | 2003 | 141 | 0.050 |
Why?
| Receptors, Serotonin | 1 | 2003 | 32 | 0.050 |
Why?
| Child, Preschool | 1 | 2017 | 9114 | 0.050 |
Why?
| Statistics as Topic | 1 | 2004 | 291 | 0.050 |
Why?
| Facial Expression | 1 | 2023 | 60 | 0.050 |
Why?
| Heterosexuality | 1 | 2023 | 29 | 0.050 |
Why?
| Practice Guidelines as Topic | 1 | 2010 | 1381 | 0.050 |
Why?
| Saliva | 1 | 2004 | 188 | 0.050 |
Why?
| Fetal Blood | 1 | 2004 | 268 | 0.050 |
Why?
| Anisotropy | 1 | 2022 | 61 | 0.050 |
Why?
| Washington | 1 | 2022 | 134 | 0.050 |
Why?
| GABA-A Receptor Antagonists | 1 | 2021 | 14 | 0.050 |
Why?
| Synaptic Transmission | 2 | 2020 | 227 | 0.050 |
Why?
| Diffusion Tensor Imaging | 1 | 2022 | 63 | 0.050 |
Why?
| Gray Matter | 1 | 2022 | 67 | 0.050 |
Why?
| Biology | 1 | 2022 | 79 | 0.050 |
Why?
| Infant | 2 | 2004 | 7943 | 0.050 |
Why?
| Proof of Concept Study | 1 | 2020 | 47 | 0.050 |
Why?
| alpha-Methyltyrosine | 1 | 1999 | 2 | 0.040 |
Why?
| RNA, Transfer | 1 | 2020 | 118 | 0.040 |
Why?
| Independent Living | 1 | 2020 | 84 | 0.040 |
Why?
| Dysuria | 1 | 2019 | 1 | 0.040 |
Why?
| Alcoholism | 1 | 2005 | 710 | 0.040 |
Why?
| Teaching Materials | 1 | 1999 | 23 | 0.040 |
Why?
| Catecholamines | 1 | 1999 | 94 | 0.040 |
Why?
| Urinary Incontinence | 1 | 2019 | 56 | 0.040 |
Why?
| Receptors, Progesterone | 1 | 2020 | 319 | 0.040 |
Why?
| Neural Pathways | 1 | 2020 | 260 | 0.040 |
Why?
| Genes, X-Linked | 1 | 2018 | 16 | 0.040 |
Why?
| Personality Inventory | 2 | 2013 | 130 | 0.040 |
Why?
| Philadelphia | 1 | 2018 | 47 | 0.040 |
Why?
| RNA, Small Interfering | 1 | 2020 | 534 | 0.040 |
Why?
| Neuronal Plasticity | 1 | 2020 | 207 | 0.040 |
Why?
| Pregnancy Trimester, Third | 1 | 2018 | 79 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2020 | 388 | 0.040 |
Why?
| Restraint, Physical | 1 | 2018 | 67 | 0.040 |
Why?
| Drug Resistance | 1 | 1999 | 158 | 0.040 |
Why?
| Substance-Related Disorders | 1 | 2006 | 942 | 0.040 |
Why?
| Histone Code | 1 | 2018 | 28 | 0.040 |
Why?
| Injections, Intravenous | 1 | 2018 | 198 | 0.040 |
Why?
| Reproduction | 1 | 1999 | 176 | 0.040 |
Why?
| Control Groups | 1 | 2017 | 10 | 0.040 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 2 | 2014 | 72 | 0.040 |
Why?
| Obstetric Labor, Premature | 1 | 2017 | 33 | 0.040 |
Why?
| Embryo, Mammalian | 1 | 2018 | 213 | 0.040 |
Why?
| Disease Susceptibility | 1 | 1999 | 316 | 0.040 |
Why?
| Betacoronavirus | 1 | 2020 | 247 | 0.040 |
Why?
| Genetic Linkage | 1 | 1998 | 294 | 0.040 |
Why?
| Anhedonia | 1 | 2017 | 9 | 0.040 |
Why?
| Patient Health Questionnaire | 1 | 2017 | 21 | 0.040 |
Why?
| Public Health | 1 | 2021 | 433 | 0.030 |
Why?
| Membrane Transport Proteins | 1 | 1998 | 138 | 0.030 |
Why?
| Placebo Effect | 1 | 2017 | 52 | 0.030 |
Why?
| Pulse | 1 | 1996 | 26 | 0.030 |
Why?
| Workplace | 1 | 2018 | 221 | 0.030 |
Why?
| Paraventricular Hypothalamic Nucleus | 1 | 2016 | 23 | 0.030 |
Why?
| Trophoblasts | 1 | 2018 | 165 | 0.030 |
Why?
| Risk Reduction Behavior | 1 | 2018 | 200 | 0.030 |
Why?
| Factor Analysis, Statistical | 1 | 2017 | 257 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2017 | 370 | 0.030 |
Why?
| Enzyme Inhibitors | 1 | 1999 | 743 | 0.030 |
Why?
| Reference Standards | 1 | 2016 | 159 | 0.030 |
Why?
| Membrane Glycoproteins | 1 | 1998 | 429 | 0.030 |
Why?
| International Cooperation | 1 | 2016 | 169 | 0.030 |
Why?
| Ambulatory Care | 1 | 1999 | 479 | 0.030 |
Why?
| Observer Variation | 1 | 2016 | 298 | 0.030 |
Why?
| Organ Size | 1 | 2016 | 434 | 0.030 |
Why?
| Corticosterone | 1 | 2016 | 211 | 0.030 |
Why?
| Pneumonia, Viral | 1 | 2020 | 334 | 0.030 |
Why?
| Coronavirus Infections | 1 | 2020 | 326 | 0.030 |
Why?
| Hot Flashes | 1 | 2015 | 72 | 0.030 |
Why?
| Aerospace Medicine | 1 | 2014 | 19 | 0.030 |
Why?
| Connecticut | 1 | 2014 | 21 | 0.030 |
Why?
| MicroRNAs | 1 | 2020 | 600 | 0.030 |
Why?
| Nerve Tissue Proteins | 1 | 1998 | 527 | 0.030 |
Why?
| Choline | 2 | 2005 | 106 | 0.030 |
Why?
| Suicide, Attempted | 1 | 2017 | 316 | 0.030 |
Why?
| Carrier Proteins | 1 | 1998 | 694 | 0.030 |
Why?
| Weightlessness | 1 | 2014 | 79 | 0.030 |
Why?
| Massachusetts | 1 | 2014 | 134 | 0.030 |
Why?
| Genotyping Techniques | 1 | 2014 | 69 | 0.030 |
Why?
| Parity | 1 | 2014 | 97 | 0.030 |
Why?
| Multimedia | 1 | 2013 | 10 | 0.030 |
Why?
| San Francisco | 1 | 2013 | 54 | 0.030 |
Why?
| Task Performance and Analysis | 1 | 2014 | 160 | 0.030 |
Why?
| Signal Processing, Computer-Assisted | 1 | 2014 | 131 | 0.030 |
Why?
| Genotype | 2 | 2014 | 1757 | 0.030 |
Why?
| Group Processes | 1 | 2013 | 53 | 0.030 |
Why?
| Pandemics | 1 | 2020 | 1310 | 0.030 |
Why?
| Attitude | 1 | 2014 | 228 | 0.020 |
Why?
| Mice | 2 | 2018 | 14843 | 0.020 |
Why?
| Adaptation, Physiological | 1 | 2014 | 484 | 0.020 |
Why?
| Mass Screening | 1 | 2017 | 979 | 0.020 |
Why?
| Dietary Supplements | 1 | 2014 | 459 | 0.020 |
Why?
| Social Support | 1 | 2014 | 528 | 0.020 |
Why?
| Blood Pressure | 1 | 1996 | 1531 | 0.020 |
Why?
| Psychometrics | 1 | 2013 | 608 | 0.020 |
Why?
| Population Groups | 1 | 2010 | 55 | 0.020 |
Why?
| Phenotype | 1 | 2017 | 2784 | 0.020 |
Why?
| Internet | 1 | 2013 | 591 | 0.020 |
Why?
| Risk Assessment | 2 | 2014 | 2958 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2014 | 1204 | 0.020 |
Why?
| Dopamine Antagonists | 2 | 2000 | 22 | 0.020 |
Why?
| DNA Primers | 1 | 2010 | 508 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 742 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 924 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 594 | 0.020 |
Why?
| Up-Regulation | 1 | 2010 | 802 | 0.020 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 75 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2016 | 4680 | 0.020 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2020 | 2087 | 0.020 |
Why?
| Tissue Distribution | 1 | 2007 | 285 | 0.020 |
Why?
| Radiopharmaceuticals | 1 | 2007 | 158 | 0.020 |
Why?
| Base Sequence | 1 | 2010 | 2114 | 0.020 |
Why?
| Prospective Studies | 1 | 2017 | 6195 | 0.020 |
Why?
| Creatine | 1 | 2005 | 51 | 0.020 |
Why?
| Fluorine Radioisotopes | 1 | 2003 | 10 | 0.010 |
Why?
| Tomography, Emission-Computed | 1 | 2003 | 58 | 0.010 |
Why?
| RNA, Messenger | 1 | 2010 | 2550 | 0.010 |
Why?
| Receptor, Serotonin, 5-HT2A | 1 | 2003 | 19 | 0.010 |
Why?
| Pyramidal Cells | 1 | 2003 | 51 | 0.010 |
Why?
| Tics | 1 | 2000 | 2 | 0.010 |
Why?
| Schizotypal Personality Disorder | 1 | 2000 | 8 | 0.010 |
Why?
| Models, Neurological | 1 | 2002 | 212 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2000 | 714 | 0.010 |
Why?
| Treatment Failure | 1 | 1999 | 330 | 0.010 |
Why?
| 1-Naphthylamine | 1 | 1996 | 1 | 0.010 |
Why?
| Clomipramine | 1 | 1996 | 2 | 0.010 |
Why?
| Buspirone | 1 | 1996 | 4 | 0.010 |
Why?
| Clonazepam | 1 | 1996 | 4 | 0.010 |
Why?
| Paroxetine | 1 | 1996 | 7 | 0.010 |
Why?
| Fenfluramine | 1 | 1996 | 13 | 0.010 |
Why?
| Analysis of Variance | 1 | 1999 | 1218 | 0.010 |
Why?
| Lithium | 1 | 1996 | 36 | 0.010 |
Why?
| Drug Tolerance | 1 | 1996 | 77 | 0.010 |
Why?
| Costs and Cost Analysis | 1 | 1996 | 196 | 0.010 |
Why?
| Drug Interactions | 1 | 1996 | 337 | 0.010 |
Why?
| Polymorphism, Genetic | 1 | 1998 | 610 | 0.010 |
Why?
|
|
Epperson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|